Rzeszow

• Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Not authorised
  2023-503522-40-00 4 Atopic Dermatitis
• A study to assess the efficacy and safety of OATD-01 for the treatment of active pulmonary sarcoidosis. Not authorised
  2023-506642-23-00 4 Active Pulmonary Sarcoidosis
• A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM 201 in Naïve-to-Tr … Not authorised
  2025-523820-26-00 5 Growth Hormone Deficiency (GHD)
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluat … Pending
  2022-502365-26-00 5 Asthma
• Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending
  2023-507427-28-00 5 seasonal allergic rhinitis and/or rhinoconjunctivitis
• A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending
  2023-509176-42-00 11 Obesity and T2D
• A Randomized, Double-Blind, Placebo Controlled, Multi - Center, Phase 1b Study to Evaluate the Safety and Tolerability of LIV001 in Patients … Pending
  2024-514520-16-00 3 mild-to-moderate active ulcerative colitis
• A Long-Term Extension Study to Evaluate the Safety and Efficacy of Ritlecitinib in Participants With Severe AA Who Have Completed Studies B7 … Pending
  2024-515439-31-00 5 Alopecia areata
• Dose-ranging study evaluating the efficacy and safety of EVO756 in adults with Chronic Spontaneous Urticaria. Pending
  2024-518786-10-01 4 Moderate to Severe Chronic Spontaneous Urticaria
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A Phase 2 trial to assess efficacy and safety of zasocitinib in moderate to severe hidradenitis suppurativa Pending
  2025-522831-33-00 4 Hidradenitis Suppurativa
• An Open label, Single Arm, Single dose Study in Pediatric Participants aged ≥2 to <12 years with a Suspected or Confirmed Bacterial Infecti … Pending
  2025-522916-17-00 3 Urinary Tract Infections
• BBT001 in Healthy Volunteers and in Adult Patients with Atopic Dermatitis Pending
  2025-522918-23-00 1 Atopic Dermatitis
• Comparison of weekly Somatrogon to daily Genotropin in children born small for gestational age or with idiopathic short stature. Pending
  2025-523832-38-00 5 Small for gestational age (SGA) and idiopathic short stature (ISS)
• A Multicenter, Open-Label, Dose Escalation Study of the Safety, Tolerability, and Efficacy of Budiodarone for the Treatment of Subjects with … Pending
  2025-523860-19-00 10 Non-permanent Atrial Fibrillation
• A Study of Enpatoran in Cutaneous Manifestations of Lupus With or Without Systemic Disease Pending
  2025-523871-44-00 5 Cutaneous Manifestations of Lupus Erythematosus With or Without System
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 5 Non-active Secondary Progressive Multiple Sclerosis (SPMS)
• Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending
  2025-524640-35-00 4 Ulcerative colitis (Inflammatory Bowel Disease)
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Recruiting
  2025-521038-27-00 5 2026-06-23 Immune system diseases
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting
  2025-524316-11-00 5 2026-06-11 Primary Progressive Multiple Sclerosis (PPMS)
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting
  2025-521590-13-00 5 2026-05-28 Moderately to Severely Active Crohn’s Disease
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Pruri … Recruiting
  2025-523404-74-00 4 2026-05-26 Prurigo Nodularis

Showing 1–24 of 329 trials